Full Suite of Cxbladder Tests Adopted by New Zealand Public Healthcare Provider Capital & Coast Dhb
Pacific Edge signs agreement with Capital & Coast District Health Board, providing access to full suite of Cxbladder products
Cancer diagnostics company, Pacific Edge (NZX: PEB), has entered into an agreement with one of New Zealand’s largest
public healthcare providers, Capital & Coast District Health Board (CCDHB), to provide its suite of Cxbladder cancer diagnostic tests for the detection,
management and monitoring of bladder cancer patients.
CCDHB is the latest in a rapidly expanding list of New Zealand public healthcare providers to incorporate Cxbladder into
their clinical pathways for urology services including the recent signing of public healthcare providers Counties
Manukau and Tairawhiti DHBs which have signed agreements within the last quarter. These new commercial users join the
existing public healthcare providers in Canterbury, Bay Of Plenty/Lakes, MidCentral and Waitemata in their use of
Cxbladder, bringing the total coverage of New Zealand’s population under contract to more than 60%.
The full suite of easy-to-use, accurate and non-invasive Cxbladder urine tests will be used by CCDHB healthcare
professionals at key decision points in the bladder cancer clinical pathway, from evaluation of blood in the urine
(haematuria) a key indicator of bladder cancer, through to management and monitoring for recurrence of the disease.
Brent Pownall, VP Commercial and Franchise at Pacific Edge, said: “Capital and Coast DHB have been using Cxbladder on a
limited scale now for a few years, and are very familiar with the different applications for the tests. Armed with the
Cxbladder test results, we are confident they can safely and effectively change the way they manage haematuria referrals
and bladder cancer surveillance for patients in the greater Wellington region, with the clear benefit for patients
identified as not requiring an invasive cystoscopy procedure.
“This is another significant commercial milestone in our goal to make Cxbladder the urologists’ preferred diagnostic
tool across the clinical pathway for haematuria and bladder cancer follow-up for New Zealand physicians and patients
alike. Today’s agreement with CCDHB provides coverage for patients for all four Cxbladder products.”
ENDS